Form 8-K - Current report:
SEC Accession No. 0001753926-25-000376
Filing Date
2025-03-03
Accepted
2025-03-03 07:00:31
Documents
14
Period of Report
2025-02-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084719_8k.htm   iXBRL 8-K 35062
2 EXHIBIT 10.1 g084719_ex10-1.htm EX-10.1 35678
  Complete submission text file 0001753926-25-000376.txt   256561

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE chro-20250225.xsd EX-101.SCH 3030
4 XBRL LABEL FILE chro-20250225_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE chro-20250225_pre.xml EX-101.PRE 22369
16 EXTRACTED XBRL INSTANCE DOCUMENT g084719_8k_htm.xml XML 3860
Mailing Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902
Business Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902 9176446313
Channel Therapeutics Corp (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41964 | Film No.: 25693731
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)